CytomX(CTMX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CTMX CytomX

盘前交易 09-08 05:43:58 EDT

3.71

+0.03

+0.82%

盘前3.65

-0.06-1.62%

04:47 EDT

最高3.73	最低3.53	成交量229.78万
今开3.64	昨收3.68	日振幅5.30%
总市值8.08亿	流通市值6.68亿	总股本2.18亿
成交额833.88万	换手率1.28%	流通股本1.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CTMX","market":"US","secType":"STK","nameCN":"CytomX","latestPrice":3.71,"timestamp":1788552000000,"preClose":3.68,"halted":0,"volume":2297761,"hourTrading":{"tag":"盘前","latestPrice":3.65,"preClose":3.71,"latestTime":"04:47 EDT","volume":3528,"amount":12544.1800848,"timestamp":1788857221061,"change":-0.06,"changeRate":-0.016173,"amplitude":0.048518},"delay":0,"changeRate":0.008152173913043424,"floatShares":180000000,"shares":217702919,"eps":-0.454847,"marketStatus":"盘前交易","change":0.03,"latestTime":"09-08 05:43:58 EDT","open":3.64,"high":3.725,"low":3.53,"amount":8338807.4321893,"amplitude":0.052989,"askPrice":3.68,"askSize":1200,"bidPrice":3.64,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.454847,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788874200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1444276800000,"exchange":"NASDAQ","adjPreClose":3.71,"preHourTrading":{"tag":"盘前","latestPrice":3.65,"preClose":3.71,"latestTime":"04:47 EDT","volume":3528,"amount":12544.1800848,"timestamp":1788857221061,"change":-0.06,"changeRate":-0.016173,"amplitude":0.048518},"postHourTrading":{"tag":"盘后","latestPrice":3.709,"preClose":3.71,"latestTime":"19:30 EDT","volume":10920,"amount":40506.876,"timestamp":1788564602812,"change":-0.001,"changeRate":-0.00027,"amplitude":0.00027},"volumeRatio":0.5121690470756407,"impliedVol":0.9428,"impliedVolPercentile":0.36},"requestUrl":"/m/hq/s/CTMX","defaultTab":"news","newsList":[{"id":"1124552718","title":"CytomX Therapeutics：Varseta-M单药注册研究拟于2027年上半年启动，剑指复发/难治性转移性结直肠癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1124552718","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124552718?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:01","pubTimestamp":1787832073,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics公司近日宣布，其候选药物Varseta-M作为单药疗法，针对复发/难治性转移性结直肠癌的潜在注册性研究，计划于2027年上半年正式启动。这一关键性里程碑的披露，标志着CytomX在肿瘤治疗领域的战略布局正稳步推进。Varseta-M有望为那些经多线治疗后仍面临疾病进展的患者带来新的治疗选择。值得注意的是，该研究定位为单药治疗方案，这意味着CytomX正探索Varseta-M独立作战的潜力，而非仅限于联合用药的范畴。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132916684","title":"CytomX Therapeutics宣布其候选药物Varsetatug Masetecan（\"Varseta-M\"）获FDA快速通道认定，用于治疗复发/难治性转移性结直肠癌（R/R mCRC）","url":"https://stock-news.laohu8.com/highlight/detail?id=1132916684","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132916684?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:01","pubTimestamp":1787832069,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics今日宣布，美国食品药品监督管理局（FDA）已授予其在研药物Varsetatug Masetecan（简称\"Varseta-M\"）快速通道资格认定，该药物拟用于治疗复发或难治性转移性结直肠癌（R/R mCRC）患者。这一里程碑式的进展，为那些在标准疗法后仍面临疾病进展的晚期结直肠癌患者带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187966317","title":"赛托姆X疗法任命亚历杭德拉·卡瓦哈尔为首席法务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1187966317","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187966317?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:02","pubTimestamp":1785758545,"startTime":"0","endTime":"0","summary":"——在掩蔽型、条件性激活生物制剂领域处于领先地位的赛托姆X疗法公司，今日正式宣布任命亚历杭德拉·卡瓦哈尔为首席法务官。在此职位上，卡瓦哈尔女士将全力支持公司的战略规划、运营执行及管线项目推进。“在这个关键节点，能够加入赛托姆X并为其愿景贡献力量，我倍感振奋，”卡瓦哈尔女士说道。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","CTMX","BK4139","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100422595","title":"新闻稿：CytomX Therapeutics 任命 Charles Fuchs 医学博士、公共卫生学硕士为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1100422595","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100422595?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:01","pubTimestamp":1785153661,"startTime":"0","endTime":"0","summary":"南旧金山，加利福尼亚州，2026年7月27日—— 隐蔽型、条件性激活生物制剂领域的领军企业 CytomX Therapeutics, Inc.今日宣布，任命 Charles Fuchs 医学博士、公共卫生学硕士为其董事会成员。他是一名获得认证的医学肿瘤学家，拥有哈佛医学院的医学博士学位和哈佛 T.H. Chan 公共卫生学院的公共卫生学硕士学位。通过其 PROBODY 治疗平台开创一条创新的局部化生物制剂管线，CytomX 的愿景是为癌症治疗创造更安全、更有效的疗法。CytomX 的临床阶段管线包括 varsetatug masetecan和 CX-801。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4139","CTMX","R","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133955723","title":"CytomX与再生元制药公司达成新协议：再生元获得6个额外靶点的选择权，潜在里程碑总额高达约40亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133955723","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133955723?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:05","pubTimestamp":1780488342,"startTime":"0","endTime":"0","summary":"生物技术公司CytomX与再生元制药公司之间的合作迎来了重大扩展。根据最新协议，再生元已获得针对6个额外靶点的选择权，此举有望将双方的合作范围进一步拓宽。协议条款显示，再生元制药公司为获得这些新靶点的选择权，已向CytomX支付了一笔预付款。若将现有合作中的潜在付款与此次新增的里程碑款项相结合，CytomX从这项合作中可能获得的总里程碑付款最高可达约40亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2089984988.USD","LU0053666078.USD","BK4139","LU2468319806.SGD","CTMX","LU0289739699.SGD","LU0320765992.SGD","LU2362540622.SGD","LU0058720904.USD","LU0882574055.USD","BK4585","LU1917777945.USD","REGN","LU2237438978.USD","LU2362541273.HKD","LU2362541513.USD","LU0114720955.EUR","LU2023250504.SGD","LU0823434583.USD","LU0889565916.HKD","LU0823434740.USD","BK4588","LU0823416689.USD","LU2106854487.HKD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185076931","title":"CytomX宣布扩大与再生元在癌症治疗条件性双特异性疗法领域的战略研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1185076931","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185076931?lang=zh_cn&edition=full","pubTime":"2026-06-03 20:03","pubTimestamp":1780488224,"startTime":"0","endTime":"0","summary":"CytomX宣布，将进一步扩大与再生元在针对癌症治疗的条件性双特异性疗法领域的战略研究合作。此次合作扩展旨在深化双方在该前沿领域的探索，共同推进新型疗法的研发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157318341","title":"CytomX任命Mamata Gokhale博士为监管事务高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1157318341","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157318341?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:01","pubTimestamp":1779105689,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics宣布，已正式任命Mamata Gokhale博士担任公司监管事务高级副总裁一职。Gokhale博士在监管合规领域拥有深厚的专业背景与丰富的实践经验，她的加入将进一步强化CytomX在药物开发与注册方面的战略布局与管理能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177494331","title":"CytomX Therapeutics宣布2.5亿美元普通股及预融资权证发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1177494331","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177494331?lang=zh_cn&edition=full","pubTime":"2026-03-18 10:47","pubTimestamp":1773802036,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics（纳斯达克代码：CTMX）今日正式公布其总额达2.5亿美元的普通股与预融资权证公开发行方案已完成定价。此次融资将通过结合普通股直接发行与预融资权证销售的方式进行，旨在为公司在肿瘤靶向疗法领域的研发管线推进提供资金支持。发行细节显示，普通股与预融资权证的发行价格将根据市场供需情况确定，最终定价方案已获得承销团认可。此次募资计划预计将强化CytomX的现金储备，加速其基于前药技术平台的创新抗癌药物临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107988125","title":"异动解读 | CytomX盘中大跌12.07%，因抗癌药物数据看好后计划募资2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107988125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107988125?lang=zh_cn&edition=full","pubTime":"2026-03-18 00:08","pubTimestamp":1773763723,"startTime":"0","endTime":"0","summary":"CytomX（CTMX）今日盘中大跌12.07%，引起了市场的广泛关注。消息面上，该公司在周一收盘后宣布计划进行2.5亿美元的募资，包括股票和预先筹资的认股权证，资金将用于继续开发其结直肠癌药物Varseta-M和其他管线项目。尽管该药物在早期试验中显示出前景，且股价在周一大涨44%，但募资行为通常会导致股价短期回调。此外，Guggenheim在周二早些时候将CytomX的目标价从10美元上调至15美元，预测Varseta-M在美国的调整后销售峰值为13亿美元。覆盖该股的所有9家券商均看涨该股，中位预测值为10.50美元。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CTMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190943112","title":"摩根大通上调CytomX评级至增持 目标价大幅提升至12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190943112","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190943112?lang=zh_cn&edition=full","pubTime":"2026-03-16 23:29","pubTimestamp":1773674950,"startTime":"0","endTime":"0","summary":"生物技术公司CytomX Therapeutics Inc（纳斯达克代码：CTMX）迎来重大利好——投资银行摩根大通最新发布研究报告，将其投资评级从\"中性\"显著上调至\"增持\"。与此同时，该机构将其目标股价从原先的7美元大幅调升至12美元，增幅超过70%，显示出对该公司未来发展前景的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115219321","title":"CytomX启动贝伐珠单抗I期研究；化疗联合Ib/II期研究拟于2026年底前展开","url":"https://stock-news.laohu8.com/highlight/detail?id=1115219321","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115219321?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:10","pubTimestamp":1773659426,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics Inc（简称CytomX）宣布已启动针对贝伐珠单抗的I期临床研究。同时，公司计划在2026年底前开展一项化疗联合疗法的Ib/II期研究。\n这两项研究旨在评估候选药物在特定患者群体中的安全性和初步疗效。贝伐珠单抗I期研究将重点关注该药物在晚期实体瘤患者中的耐受性与药代动力学特征。而拟启动的Ib/II期研究则将探索化疗联合方案在特定癌症类型中的治疗潜力。\n公司表示，上述进展符合其推进精准肿瘤疗法的战略规划。通过阶段性临床试验，CytomX期望为后续临床开发提供关键数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190684552","title":"CytomX的Varsetatug Masetecan（EpCAM Probody® ADC）持续展现积极数据，有望成为后线结直肠癌新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1190684552","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190684552?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:09","pubTimestamp":1773659354,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics公司研发的Varsetatug Masetecan（EpCAM Probody®抗体偶联药物）最新临床数据持续呈现积极信号，这项创新疗法或将为晚期结直肠癌患者提供新的治疗选择。数据显示，该药物在经多轮治疗的患者群体中仍能保持显著抗肿瘤活性，其独特的作用机制有望突破现有后线治疗瓶颈。\n作为靶向EpCAM的精准疗法，该ADC药物通过智能探针技术有效区分病变组织与健康细胞，在提升疗效的同时显著降低毒副作用。最新临床证据进一步验证了其耐受性与临床获益率的可持续性，为后续适应症拓展奠定基础。随着结直肠癌后线治疗需求日益迫切，该疗法的开发进展备受行业关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122849062","title":"CytomX Therapeutics第四季度GAAP每股收益$0.23，超出$(0.20)预期，销售额$38.09M超出$19.42M预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1122849062","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122849062?lang=zh_cn&edition=full","pubTime":"2025-03-07 05:40","pubTimestamp":1741297242,"startTime":"0","endTime":"0","summary":"CytomX Therapeutics  报告季度每股收益$0.23，超过分析师共识预期的$，增长215%。与去年同期的每股收益$0.01相比增加了2200%。以上内容来自Benzinga Earnings专栏，原文如下：$CytomX$ $Therapeutics$  reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $ by 215 percent. This is a 2200 percent increase over earnings of $0.01 per share from the same period last year.  The company reported quarterly sales of $38.09 million which beat the analyst consensus estimate of $19.42 million by 96.19 percent.  This is a 43.17 percen","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CytomX Therapeutics第四季度GAAP每股收益$0.23，超出$(0.20)预期，销售额$38.09M超出$19.42M预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510863283","title":"Cytomx Therapeutics, Inc.盘中异动 大幅下挫5.40%报0.795美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863283","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510863283?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:37","pubTimestamp":1739198253,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时37分，Cytomx Therapeutics, Inc.股票出现异动，股价快速下跌5.40%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.涨幅较大，Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.、Conduit Pharmaceuticals Inc.较为活跃，换手率分别为987.05%、664.57%、268.03%，振幅较大的相关个股有Ocean Biomedical, Inc.、Invivyd, Inc.、Nls Pharmaceutics Ltd.，振幅分别为34.46%、29.90%、22.45%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223734abc9a6d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223734abc9a6d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTMX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509049252","title":"Cytomx Therapeutics, Inc.盘中异动 股价大跌5.08%报0.890美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509049252","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509049252?lang=zh_cn&edition=full","pubTime":"2025-02-07 01:36","pubTimestamp":1738863387,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日01时36分，Cytomx Therapeutics, Inc.股票出现波动，股价急速下挫5.08%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。其相关个股中，Lipella Pharmaceuticals Inc.、Palatin Technologies, Inc.、Geovax Labs Inc C/Wts 29/09/2025涨幅较大，Lipella Pharmaceuticals Inc.、Transcode Therapeutics, Inc.、Azitra Inc较为活跃，换手率分别为6297.64%、1646.64%、165.02%，振幅较大的相关个股有Lipella Pharmaceuticals Inc.、Palatin Technologies, Inc.、Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 ，振幅分别为125.58%、58.78%、53.02%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207013627961a34f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207013627961a34f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTMX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509237797","title":"Cytomx Therapeutics, Inc.盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509237797","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509237797?lang=zh_cn&edition=full","pubTime":"2025-02-06 02:43","pubTimestamp":1738781037,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日02时43分，Cytomx Therapeutics, Inc.股票出现异动，股价快速上涨5.07%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.26%。其相关个股中，Invivyd, Inc.、Transcode Therapeutics, Inc.、Celularity Inc C/Wts 16/07/2026 涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4590.20%、2316.60%、1731.32%，振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Invivyd, Inc.，振幅分别为132.24%、99.51%、63.99%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206024357abc3b239&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206024357abc3b239&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CTMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507967236","title":"Cytomx Therapeutics, Inc.盘中异动 大幅上涨5.90%报0.868美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507967236","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507967236?lang=zh_cn&edition=full","pubTime":"2025-01-31 03:17","pubTimestamp":1738264624,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日03时17分，Cytomx Therapeutics, Inc.股票出现波动，股价急速上涨5.90%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Immatics N V C/Wts 01/07/2025 涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1787.15%、302.63%、244.43%，振幅较大的相关个股有Cero Therapeutics Holdings, Inc.、Immatics N V C/Wts 01/07/2025 、Alterity Therapeutics Limited，振幅分别为65.98%、64.10%、61.86%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131031705a23483e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131031705a23483e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CTMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506893882","title":"Cytomx Therapeutics, Inc.盘中异动 急速拉升5.75%报0.918美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506893882","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506893882?lang=zh_cn&edition=full","pubTime":"2025-01-25 00:45","pubTimestamp":1737737132,"startTime":"0","endTime":"0","summary":"北京时间2025年01月25日00时45分，Cytomx Therapeutics, Inc.股票出现波动，股价快速拉升5.75%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Neuphoria Therapeutics Inc.、Evaxion Biotech As、Pmgc Holdings Inc.涨幅较大，Evaxion Biotech As、Pmgc Holdings Inc.、Transcode Therapeutics, Inc.较为活跃，换手率分别为3933.45%、2145.02%、1600.40%，振幅较大的相关个股有Neuphoria Therapeutics Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、Evaxion Biotech As，振幅分别为193.98%、134.08%、112.09%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125004532abb76cc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250125004532abb76cc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","CTMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503915647","title":"Cytomx Therapeutics, Inc.盘中异动 早盘股价大跌5.07%报0.815美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503915647","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503915647?lang=zh_cn&edition=full","pubTime":"2025-01-16 23:08","pubTimestamp":1737040081,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日23时08分，Cytomx Therapeutics, Inc.股票出现异动，股价快速下挫5.07%。截至发稿，该股报0.815美元/股，成交量13.2748万股，换手率0.17%，振幅4.13%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.01%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116230802986893eb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116230802986893eb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","CTMX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2501977691","title":"Cytomx Therapeutics, Inc.盘中异动 早盘大幅下跌5.15%报0.968美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501977691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2501977691?lang=zh_cn&edition=full","pubTime":"2025-01-08 23:12","pubTimestamp":1736349121,"startTime":"0","endTime":"0","summary":"北京时间2025年01月08日23时12分，Cytomx Therapeutics, Inc.股票出现异动，股价快速下挫5.15%。Cytomx Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Sana Biotechnology, Inc.、Silo Pharma, Inc.、Vir Biotechnology, Inc.涨幅较大，Silo Pharma, Inc.、60 Degrees Pharmaceuticals, Inc.、Nls Pharmaceutics Ltd.较为活跃，换手率分别为2452.71%、559.74%、527.80%，振幅较大的相关个股有Sana Biotechnology, Inc.、Silo Pharma, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 ，振幅分别为154.55%、139.44%、68.53%。Cytomx Therapeutics, Inc.公司简介：CytomX Therapeutics Inc 是一家在美国运营的专注于肿瘤学的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108231201a21a5d49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108231201a21a5d49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CTMX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cytomx.com","stockEarnings":[{"period":"1week","weight":0.1558},{"period":"1month","weight":0.1075},{"period":"3month","weight":0.2367},{"period":"6month","weight":-0.2073},{"period":"1year","weight":0.7667},{"period":"ytd","weight":-0.1291}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"CytomX Therapeutics, Inc.于2010年9月在特拉华州注册成立，其运营始于2008年。该公司是一家临床阶段的、专注于肿瘤学的生物制药公司，基于其专有的PROBODY技术平台开发创新疗法。该平台能够实现条件性激活的生物制剂，旨在选择性靶向肿瘤，其最先进的临床项目Varseta-M是一种正在针对结直肠癌进行1期开发的抗体药物偶联物。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.095227},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.029398},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.042559},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.017017},{"month":5,"riseRate":0.363636,"avgChangeRate":0.163192},{"month":6,"riseRate":0.454545,"avgChangeRate":-0.029036},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.060173},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.007125},{"month":9,"riseRate":0.363636,"avgChangeRate":0.041004},{"month":10,"riseRate":0.3,"avgChangeRate":-0.069949},{"month":11,"riseRate":0.818182,"avgChangeRate":0.178681},{"month":12,"riseRate":0.454545,"avgChangeRate":0.003835}],"exchange":"NASDAQ","name":"CytomX","nameEN":"CytomX Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CytomX(CTMX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CytomX(CTMX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CytomX,CTMX,CytomX股票,CytomX股票老虎,CytomX股票老虎国际,CytomX行情,CytomX股票行情,CytomX股价,CytomX股市,CytomX股票价格,CytomX股票交易,CytomX股票购买,CytomX股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CytomX(CTMX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CytomX(CTMX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}